<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Keech, Anthony</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">FIELD (Fenofibrate Intervention and Event Lowering in Diabetes)</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-17</style></pages><abstract><style  face="normal" font="default" size="100%">FIELD (Fenofibrate Intervention and Event lowering in Diabetes), the largest type 2 diabetes intervention trial, looked at fenofibrate's effects on coronary mortality and morbidity. FIELD lead investigator professor Anthony Keech, MD, University of Sydney, Australia, stated “Atherogenic diabetic dyslipidemia may be particularly amenable to fibrate therapy.” He noted that fenofibrate reduces triglycerides (TG), total cholesterol (TC), and LDL cholesterol while increasing HDL cholesterol.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">5</style></volume></record></records></xml>